These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22028136)

  • 21. Combination treatment with guanfacine extended release and blonanserin for Tourette's syndrome comorbid with attention deficit hyperactivity disorder.
    Kawabe K; Horiuchi F; Ueno SI
    Psychiatry Clin Neurosci; 2019 Dec; 73(12):762-763. PubMed ID: 31588606
    [No Abstract]   [Full Text] [Related]  

  • 22. Guanfacine use in children with attention deficit hyperactivity disorder.
    Cohn LM; Caliendo GC
    Ann Pharmacother; 1997; 31(7-8):918-9. PubMed ID: 9220058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors.
    Capone GT; Brecher L; Bay M
    J Child Neurol; 2016 Jul; 31(8):957-64. PubMed ID: 26936058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.
    Arnsten AF; Scahill L; Findling RL
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):393-406. PubMed ID: 17822336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
    Mattingly GW; Anderson RH
    CNS Spectr; 2016 Dec; 21(S1):45-59. PubMed ID: 28044946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder.
    Hunt RD; Arnsten AF; Asbell MD
    J Am Acad Child Adolesc Psychiatry; 1995 Jan; 34(1):50-4. PubMed ID: 7860456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How should we evaluate and treat ADHD in children and adolescents?
    Ambalavanan G; Holten KB
    J Fam Pract; 2005 Dec; 54(12):1058-9. PubMed ID: 16321344
    [No Abstract]   [Full Text] [Related]  

  • 28. A case of excessive weight gain with guanfacine extended release: 9.53 kg in 4 weeks.
    Khan MA; Jain G; Soltys SM; Takahashi A
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):256-7. PubMed ID: 22537187
    [No Abstract]   [Full Text] [Related]  

  • 29. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.
    Scahill L
    CNS Drugs; 2009; 23 Suppl 1():43-9. PubMed ID: 19621977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric Guanfacine Toxicity with Severely Elevated Plasma Concentration.
    Downs JW; Wills BK; Cumpston KL; Wolf CE; Rose SR
    J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):473-474. PubMed ID: 32667829
    [No Abstract]   [Full Text] [Related]  

  • 31. [An update on the pharmacological treatment of attention deficit hyperactivity disorder: lisdexamphetamine and extended-release guanfacine].
    Martin Fernandez-Mayoralas D; Fernandez-Perrone AL; Munoz-Jareno N; Fernandez-Jaen A
    Rev Neurol; 2017 Mar; 64(s02):S1-S8. PubMed ID: 28272733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Attention deficit disorders with hyperactivity in adulthood; implications for diagnosis and treatment].
    Kooij JJ; Goekoop JG; Gunning WB
    Ned Tijdschr Geneeskd; 1996 Sep; 140(37):1848-51. PubMed ID: 8927155
    [No Abstract]   [Full Text] [Related]  

  • 33. Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders.
    Rowles BM; Findling RL
    Dev Disabil Res Rev; 2010; 16(3):273-82. PubMed ID: 20981766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonidine for treatment of attention-deficit/hyperactivity disorder.
    Med Lett Drugs Ther; 1996 Dec; 38(989):109-10. PubMed ID: 8957471
    [No Abstract]   [Full Text] [Related]  

  • 35. An open-label, prospective study of guanfacine in children with ADHD and tic disorders.
    Boon-yasidhi V; Kim YS; Scahill L
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S156-62. PubMed ID: 16856436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms.
    Stahl SM
    J Clin Psychiatry; 2010 Mar; 71(3):223-4. PubMed ID: 20331927
    [No Abstract]   [Full Text] [Related]  

  • 37. Guanfacine in children with autism and/or intellectual disabilities.
    Handen BL; Sahl R; Hardan AY
    J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder.
    Connor DF; Fletcher KE; Swanson JM
    J Am Acad Child Adolesc Psychiatry; 1999 Dec; 38(12):1551-9. PubMed ID: 10596256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conflicting information from TGA versus FDA may undermine compliance with use of medication.
    Beckmann KM
    Med J Aust; 2013 Jul; 199(1):28-9. PubMed ID: 23829255
    [No Abstract]   [Full Text] [Related]  

  • 40. Nonstimulant Treatments for ADHD.
    Newcorn JH; Krone B; Dittmann RW
    Child Adolesc Psychiatr Clin N Am; 2022 Jul; 31(3):417-435. PubMed ID: 35697393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.